Bukwang sets eyes on overseas markets

Bukwang Pharm is going all-out to make inroads into foreign countries as the domestic market shows clear signs of reaching saturation point.

The company is adopting its own strategy and action plans in its quest for expansion.
Bukwang has already executed two in-licensing agreements with foreign company and universities - YN968D1 (apatinib) and novel anti-hepatitis B drug.

Apatinib was ...